Janssen Reports Positive Topline Phase 2 Results for Nipocalimab in Pregnant Individuals at High Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
SPRING HOUSE, PENNSYLVANIA, February 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the proof-of-concept Phase 2 open-label UNITY clinical trial for the treatment of pregnant adults at high risk for severe hemolytic disease of the fetus and newborn (HDFN). HDFN is a serious and rare condition which can cause life-threatening anemia in the fetus. It occurs when the blood types of a pregnant individual and their fetus are incompatible.1 The trial met the primary endpoint, with the majority of pregnant patients who received nipocalimab achieving a live b...
Source: Johnson and Johnson - February 8, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Data on Diagnosing Demyelinating Polyradiculoneuropathy New Data on Diagnosing Demyelinating Polyradiculoneuropathy
There is a potential role for the lymphocyte to monocyte ratio as a predictive and prognostic biomarker for CIDP.First Look (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 1, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
HIZENTRA(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) Receives Orphan-Drug Exclusivity for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for maintenance therapy in CIDP qualifies for marketing exclusivity
KING OF PRUSSIA, Pa., Dec. 9, 2019 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring ann... Biopharmaceuticals, Neurology, FDA CSL Behring, HIZENTRA, Immune Globulin, Demyelinating Polyn (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 9, 2019 Category: Pharmaceuticals Source Type: news
5 Things to Know About CIDP 5 Things to Know About CIDP
While a rare, often perplexing disease, chronic inflammatory demyelinating polyneuropathy is a treatable condition.Medscape Neurology (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - September 20, 2019 Category: Infectious Diseases Tags: Neurology & Neurosurgery Article Source Type: news
What is the Recurrence Rate for Guillian-Barr é Syndrome and Should She Get An Influenza Vaccine?
Discussion
Guillian-Barré syndrome (GBS) is an acquired, acute, inflammatory, demyelinating polyneuropathy. It is the most common cause of acute and subacute flaccid paralysis in children. GBS causes about 0.4-1.3 cases per 100,000 persons/year in children. It can occur in any age group and the incidence increases among all age groups until a peak in the 50s. Both genders are affected and there may be a slight increase in males.
GBS usually occurs 2-4 weeks after a prodromal gastroenteritis or respiratory illness. GBS causes autoantibody production against Schwann cells of the neuron and the axon itself. There is ...
Source: PediatricEducation.org - November 19, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
‘ This Is How I Save My Life ’ Excerpt From Amy B. Scher
Amy B. Scher’s “This Is How I Save My Life” is the true story of a fiery young woman diagnosed with late-stage, chronic Lyme disease whose journey takes her from near-death in California to a trip around the world in search of her ultimate salvation. This excerpt coincides with the book’s release in paperback from Gallery Books, an imprint CBS sister company Simon & Schuster.
I am twenty-eight years old when I arrive in magnificent India. I am here with my parents, an updated vaccine record, and a visa, searching for something I cannot find at home: a cure. In a tiny hospital on the outskirts of Delhi, a female...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 21, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Simon and Schuster Source Type: news
FDA approves CSL Behring rare disease treatment
The Food and Drug Administration granted marketing clearance Friday for Hizentra, a treatment for chronic inflammatory demyelinating polyneuropathy developed by CSL Behring.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare autoimmune disorder that affects the peripheral nerves and may cause permanent nerve damage.
The condition, which afflicts an estimated 40,000 people in the United States, can cause nerve numbness or tingling, muscle weakness, fa tigue and other symptoms. An… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 16, 2018 Category: Biotechnology Authors: John George Source Type: news
FDA Approves Hizentra(R) (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
First and only subcutaneous immunoglobulin (SCIg) approved for the treatment of CIDP based on the largest controlled clinical study in CIDP
KING OF PRUSSIA, Pa., March 16, 2018 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader ... Biopharmaceuticals, FDA CSL Behring, Hizentra, Immune Globulin, CIDP (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 16, 2018 Category: Pharmaceuticals Source Type: news
FDA Approves Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
KING OF PRUSSIA, Pa. – March 16, 2018 – Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) approved Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) as the first and only... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 16, 2018 Category: Drugs & Pharmacology Source Type: news
EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP EU Clears First Subcutaneous Immunoglobulin (Hizentra) for CIDP
Hizentra is the first subcutaneous immunoglobulin approved as maintenance therapy to prevent relapse of neuromuscular disability and impairment in chronic inflammatory demyelinating polyneuropathy.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
Medical News Today: What to know about CIDP
A look at chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where that causes nerve damage. Included is detail on treatment. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 25, 2018 Category: Consumer Health News Tags: Neurology / Neuroscience Source Type: news
Subcutaneous Immunoglobulin Effective for Maintenance in CIDP Subcutaneous Immunoglobulin Effective for Maintenance in CIDP
Subcutaneous immunoglobulin is effective and convenient maintenance therapy for chronic inflammatory demyelinating polyneuropathy, the PATH trial has shown. Local reactions decreased with repeat dosing.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
CSL Behring Announces FDA Approval of Privigen [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
KING OF PRUSSIA, Pa. — 14 September 2017 -- Global biotherapeutics leader CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 14, 2017 Category: Drugs & Pharmacology Source Type: news
